Exclusive: Germany to take stake in unlisted CureVac - sources
Reuters
Published Jun 15, 2020 10:57
Updated Jun 15, 2020 11:45
By Ludwig Burger and Rene Wagner
FRANKFURT/BERLIN (Reuters) - Germany will take a stake in unlisted biotech firm CureVac, which is working on a COVID-19 vaccine, four people familiar with the plan told Reuters on Monday.
Two of the sources described the size of the stake as substantial, without providing details.
Curevac, the German economy ministry and dievini Hopp BioTech holding, which is the investment vehicle of CureVac's controlling shareholder Dietmar Hopp, declined to comment.
Dievini Hopp said in a statement earlier on Monday that it will join Economy Minister Peter Altmaier and CureVac's acting Chief Executive Franz-Werner Haas for a press briefing at 1030 GMT, without providing details.
Reported attempts by the United States government to acquire Curevac or its assets in March stirred a political backlash in Germany, with Altmaier and Interior Minister Horst Seehofer at the time voicing support for keeping CureVac German.
Reflecting the sensitivity about ownership of the country's two coronavirus vaccine developers - CureVac and BioNTech (O:BNTX) - Berlin in May gave itself new powers to veto hostile foreign takeover bids for healthcare companies.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.